FDA Rejects Trump Admin’s Autism Drug Claims: Leucovorin Use Spiked 71% Despite Limited Evidence

The Food and Drug Administration (FDA) has clarified its stance on the generic drug leucovorin, approving it for the treatment of a rare genetic condition but rejecting its apply as a broad-spectrum treatment for autism, a reversal that follows enthusiastic promotion of the drug by officials during the Trump administration. The decision comes after a surge in prescriptions for leucovorin following claims that it could benefit a significant percentage of children with autism.

In September 2025, then-FDA Commissioner Marty Makary publicly touted leucovorin as a potentially promising treatment for autism, stating in a press release that a “growing body of evidence” suggested its effectiveness. At a White House event, Makary went further, suggesting the drug could help “20, 40, 50 percent of kids with autism,” and estimating that “hundreds of thousands of kids” could benefit. These statements, amplified by Health and Human Services Secretary Robert F. Kennedy Jr., led to a notable increase in prescriptions. A study published in The Lancet revealed a 71 percent jump in new outpatient prescriptions of leucovorin for children aged 5 to 17 in the three months following the administration’s pronouncements.

FDA Narrows Approval to Cerebral Folate Deficiency

However, the FDA’s recent announcement significantly narrowed the scope of leucovorin’s approved use. The agency has approved the drug specifically for the treatment of cerebral folate transport deficiency (CFD), a rare genetic condition in adults caused by a mutation in the folate receptor 1 gene (CFD-FOLR1). Senior FDA officials, speaking to the Associated Press, explained that they found insufficient evidence to support expanding the drug’s use to autism. This decision represents a clear departure from the earlier, more optimistic messaging from administration officials.

The FDA’s shift in position was further underscored by the fact that one of the largest studies supporting leucovorin’s use for autism was retracted last month due to errors in its data and statistical analysis. Reanalysis of the data failed to reproduce the original positive findings, casting doubt on the initial claims of efficacy. Leucovorin, similarly known as folinic acid, is a reduced form of folic acid used to treat impaired folate metabolism.

The Role of Political Pressure and Public Perception

The episode raises questions about the influence of political pressure on scientific and medical decision-making. The Trump administration’s enthusiastic endorsement of leucovorin, despite limited evidence, fueled hope among families affected by autism. The subsequent surge in prescriptions demonstrates the power of such endorsements to shape medical practice, even in the absence of conclusive scientific backing. The situation highlights the importance of rigorous scientific evaluation and independent regulatory oversight in ensuring the safety and efficacy of medical treatments.

The FDA’s decision also underscores the complexities of autism research. Autism spectrum disorder is a highly heterogeneous condition, meaning it manifests differently in each individual. Finding a single, universally effective treatment has proven to be a significant challenge. While research continues to explore potential therapeutic interventions, families and caregivers must rely on evidence-based approaches and consult with qualified healthcare professionals.

Understanding Cerebral Folate Deficiency

The FDA’s approved use of leucovorin for cerebral folate deficiency offers a targeted treatment for a specific, albeit rare, genetic condition. CFD is characterized by an inability to transport folate into the cerebrospinal fluid, leading to neurological problems. Leucovorin bypasses the defective folate transport system, providing the brain with the necessary folate. This approval provides a much-needed treatment option for individuals diagnosed with this condition.

Impact on Autism Community and Future Research

The FDA’s decision is likely to be met with disappointment by some members of the autism community who had hoped for a new treatment option. However, experts emphasize the importance of focusing on evidence-based interventions and avoiding unproven therapies. The situation serves as a cautionary tale about the dangers of relying on anecdotal evidence or premature claims of efficacy.

Looking ahead, continued research is crucial to understanding the underlying causes of autism and developing effective treatments. Researchers are exploring a wide range of potential interventions, including behavioral therapies, genetic studies and pharmacological approaches. The FDA’s decision to prioritize rigorous scientific evaluation will be essential in ensuring that any future treatments are safe and effective.

The initial enthusiasm surrounding leucovorin also prompted increased scrutiny of the drug’s potential side effects. While generally considered safe, leucovorin can cause adverse reactions in some individuals. The FDA’s approval for CFD includes specific warnings and precautions to minimize the risk of side effects. It is crucial for healthcare professionals to carefully monitor patients receiving leucovorin and to report any adverse events to the FDA.

The Controversy Surrounding Marty Makary’s Claims

The role of Marty Makary, the former FDA Commissioner, in promoting leucovorin for autism has drawn criticism from some quarters. Critics argue that his statements were premature and lacked sufficient scientific support. Makary’s claims were based on what he described as a “growing body of evidence,” but this evidence was later found to be inconclusive. The retraction of the key study further undermined the basis for his assertions.

The situation raises broader questions about the transparency and accountability of the FDA. Some observers have called for greater oversight of the agency’s communications and for stricter guidelines on the dissemination of information about unapproved uses of drugs. The FDA has not yet responded to these calls for greater transparency.

What So for Patients and Families

For families affected by autism, the FDA’s decision means that leucovorin is not currently an approved treatment option. Parents should continue to work with their healthcare providers to develop individualized treatment plans based on evidence-based interventions. These interventions may include behavioral therapies, educational support, and other therapies tailored to the specific needs of the child.

It is important to remember that autism is a complex condition with no single cure. While research continues to advance our understanding of autism, there is currently no medication that can eliminate the core symptoms of the disorder. However, a variety of interventions can help individuals with autism to manage their symptoms and improve their quality of life.

The FDA’s approval of leucovorin for cerebral folate deficiency does offer hope for individuals with this rare genetic condition. Families affected by CFD should consult with their healthcare providers to determine if leucovorin is an appropriate treatment option. The FDA’s website provides additional information about CFD and leucovorin, including prescribing information and safety warnings. Learn more about the FDA approval here.

The agency’s decision to narrow the approval of leucovorin underscores the importance of relying on scientific evidence and independent regulatory oversight when evaluating medical treatments. While the search for effective autism treatments continues, families and caregivers should prioritize evidence-based approaches and consult with qualified healthcare professionals.

The next step in this situation will be the ongoing monitoring of patients receiving leucovorin for cerebral folate deficiency, as well as continued research into potential treatments for autism. The FDA will likely continue to evaluate new evidence as it becomes available and will update its guidance accordingly. Families and healthcare providers are encouraged to stay informed about the latest developments in autism research and treatment.

Do you have thoughts on the FDA’s decision? Share your comments below, and please share this article with your network to help spread awareness.